20-Feb-2026
No headlines found.
Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Globe Newswire (Thu, 5-Feb 4:10 PM ET)
Globe Newswire (Fri, 23-Jan 7:00 AM ET)
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook
Globe Newswire (Thu, 8-Jan 4:05 PM ET)
Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference
Globe Newswire (Mon, 1-Dec 7:00 AM ET)
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
Eledon Pharmaceuticals trades on the NASDAQ stock market under the symbol ELDN.
As of February 20, 2026, ELDN stock price declined to $2.19 with 1,079,758 million shares trading.
ELDN has a beta of 1.90, meaning it tends to be more sensitive to market movements. ELDN has a correlation of 0.10 to the broad based SPY ETF.
ELDN has a market cap of $164.33 million. This is considered a Micro Cap stock.
In the last 3 years, ELDN traded as high as $5.54 and as low as $1.07.
The top ETF exchange traded funds that ELDN belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.
ELDN has underperformed the market in the last year with a return of -49.5%, while SPY returned +14.1%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in ELDN shares. However, ELDN has outperformed the market in the last 3 month and 2 week periods, returning +57.6% and 0.0%, while SPY returned +6.0% and -0.2%, respectively. This indicates ELDN has been having a stronger performance recently.
ELDN support price is $2.12 and resistance is $2.33 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ELDN shares will trade within this expected range on the day.